Advertisement
U.S. markets open in 2 hours 59 minutes
  • S&P Futures

    5,305.25
    -3.00 (-0.06%)
     
  • Dow Futures

    40,135.00
    -9.00 (-0.02%)
     
  • Nasdaq Futures

    18,489.00
    -14.75 (-0.08%)
     
  • Russell 2000 Futures

    2,136.80
    -1.60 (-0.07%)
     
  • Crude Oil

    81.93
    +0.58 (+0.71%)
     
  • Gold

    2,220.40
    +7.70 (+0.35%)
     
  • Silver

    24.62
    -0.13 (-0.51%)
     
  • EUR/USD

    1.0790
    -0.0040 (-0.37%)
     
  • 10-Yr Bond

    4.1960
    0.0000 (0.00%)
     
  • Vix

    12.97
    +0.19 (+1.49%)
     
  • GBP/USD

    1.2611
    -0.0027 (-0.21%)
     
  • USD/JPY

    151.4020
    +0.1560 (+0.10%)
     
  • Bitcoin USD

    70,364.74
    +219.92 (+0.31%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,960.01
    +28.03 (+0.35%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

Hoth Therapeutics' HT-003 Shows Encouraging Action Against Acne In Animal Model

  • Hoth Therapeutics Inc (NASDAQ: HOTH) has announced that its HT-003 group of assets has yielded positive results in an in vivo acne therapeutic model.

  • The model showed that HT-003 reduces toll-like receptor 2 (TLR2) expression, one of the most critical pathways for acne pathophysiology.

  • The study also showed that HT-003 reduces the expression of numerous cytokines critical for acne pathophysiology that are also relevant therapeutic markers for other inflammatory-driven skin diseases.

  • HT-003 is a group of retinoic acid metabolism blocking agents, novel agents that prevent the breakdown of retinoic acid. Retinoic acid acts as an anti-inflammatory agent in the body.

  • In addition to the dermatologic application, Hoth Therapeutics is exploring the potential application of HT-003 assets in inflammatory bowel disorders.

  • Price Action: HOTH shares are down 2.01% at $1.46 during the market session on the last check Tuesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement